About

The Murakami Lab at DFCI studies minimal residual disease in B-cell leukemia and lymphoma and aims to translate mechanistic discoveries into individualized therapies to improve patient outcomes by utilizing our repository of preclinical models including patient-derived xenograft (PDX) mouse models, access to conventional and experimental therapeutic agents, expertise in lymphoid genomics and bioinformatics, novel single-cell biophysical and molecular profiling platforms, and involvement in early phase clinical trials.